To set a novel, unified industry standard,
addressing the challenge of trans-membrane
delivery of genetic drugs for clinical use.

Play With Sound

To set a novel, unified industry standard, addressing the challenge of trans-membrane delivery of genetic drugs for clinical use.​

About

Aposense is a highly innovative Israeli biotechnology company with full capacity research facilities and scientific leadership, headed by the Professor Roger D Kornberg, Nobel Prize Laureate, 2006.  Aposense developed a universal platform entitled Molecular Nano-Motors (MNMs) for the delivery of genetic drugs, such as siRNA, into cells based on a novel mechanism of action, utilizing membrane electrical forces.

Meet our team

Our Technology

Fascinated by the fact that every cell harbours its own discrete and strong powerhouse, Aposense developed rationally designed Molecular Nano-Motors, being novel small-molecule chemical entities, capable of “energy mining” from the Internal Membrane Electric Field, and its translation into kinetic energy, for movement within the hydrophobic membrane core.
Learn More

Therapeutic Areas

Platform technology extending widely beyond the Liver, unlocking novel targets for genetic therapeutics.
Platform technology with wide applicability in terms of therapeutic areas and genetic cargo.
Here are our prioritized therapeutic areas Aposense Molecular Nano Motors also has the potential to address additional therapeutic areas such as gastrointestinal, cardiovascular, eye, autoimmune.

These therapeutic areas are currently being investigated by Aposense’s team:

Lungs

CNS

Hearing Disorders

GI

Read More

News